Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.

Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.

Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). The EGFR-T790M secondary mutation is responsible for half of acquired resistance cases,...

Full description

Bibliographic Details
Main Authors: Silvia La Monica, Cristina Caffarra, Francesca Saccani, Elena Galvani, Maricla Galetti, Claudia Fumarola, Mara Bonelli, Andrea Cavazzoni, Daniele Cretella, Rita Sirangelo, Rita Gatti, Marcello Tiseo, Andrea Ardizzoni, Elisa Giovannetti, Pier Giorgio Petronini, Roberta R Alfieri
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3805532?pdf=render

Internet

http://europepmc.org/articles/PMC3805532?pdf=render

Similar Items